0001628280-18-012395.txt : 20181009 0001628280-18-012395.hdr.sgml : 20181009 20181009160554 ACCESSION NUMBER: 0001628280-18-012395 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20181009 DATE AS OF CHANGE: 20181009 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OPIANT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001385508 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-90404 FILM NUMBER: 181113705 BUSINESS ADDRESS: STREET 1: 201 SANTA MONICA BOULEVARD STREET 2: SUITE 500 CITY: SANTA MONICA STATE: CA ZIP: 90401 BUSINESS PHONE: (310) 598-5410 MAIL ADDRESS: STREET 1: 201 SANTA MONICA BOULEVARD STREET 2: SUITE 500 CITY: SANTA MONICA STATE: CA ZIP: 90401 FORMER COMPANY: FORMER CONFORMED NAME: Lightlake Therapeutics Inc. DATE OF NAME CHANGE: 20091009 FORMER COMPANY: FORMER CONFORMED NAME: Madrona Ventures, Inc. DATE OF NAME CHANGE: 20070108 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Pollack Kevin CENTRAL INDEX KEY: 0001553236 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 150 RAINVILLE ROAD CITY: TARPON SPRINGS STATE: FL ZIP: 34689 SC 13D/A 1 kevinpollack-amendmentno1t.htm SC 13D/A Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Opiant Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $.001 per share
(Title of Class of Securities)
683750103
(CUSIP Number)
Kevin Pollack
c/o Sheppard Mullin Richter & Hampton LLP
Attn: Robert L. Wernli, Jr., Esq.
12275 El Camino Real, Suite 200
San Diego, CA 92130
(858) 720-8900
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
October 4, 2018
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box:
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






CUSIP No. 683750103
 
(1) Names of Reporting Persons 
Kevin Pollack
 
(2) Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ¨  (b)  ¨
(3) SEC Use Only
(4) SOURCE of Funds (See Instructions) 
PF
(5) Check Box if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ¨
(6) Citizenship or Place Of Organization 
United States
Number of Shares Beneficially Owned by Each Reporting Person With
(7) Sole Voting Power
148,834 shares
(8) Shared Voting Power
0 shares
(9) sole dispositive power
148,834 shares
(10) Shared Dispositive Power
0 shares
(11) Aggregate Amount Beneficially Owned by Each Reporting Person 
148,834 shares
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨
(13) Percent of Class Represented by Amount in Row (11) 
4.99% *
(14) Type of Reporting Person (See Instructions) 
IN



*
Percentage calculated based on 2,982,665 shares of Common Stock, par value $.001 per share, of Opiant Pharmaceuticals, Inc. (the "Issuer") which is the total number of shares estimated to be outstanding as of September 11, 2018, as reported in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission on September 26, 2018.











2

Explanatory Note
This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D filed on February 28, 2018 (the “Schedule 13D”) by the Reporting Person relating to the Common Stock of the Issuer. Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Schedule 13D. All references in the Schedule 13D and this Amendment to the “Statement” shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment.
Item 4.    Purpose of Transaction.
Item 4 is amended to add the following:
On October 4, 2018, the Reporting Person entered into a letter agreement with the Issuer, pursuant to which the Reporting Person and the Issuer agreed that the Reporting Person shall not have the right to exercise any portion of the Issuer stock options held by the Reporting Person to the extent that, after giving effect to such exercise, the Reporting Person, his affiliates and any persons acting as a group together with the Reporting Person or his affiliates, would beneficially own in excess of 4.99% of the outstanding shares of Common Stock of the Issuer. Upon not less than 61 days’ prior notice to the Issuer, the Reporting Person may increase such beneficial ownership limitation (but not above 9.99%) or decrease such limitation. The beneficial ownership limitation will automatically lapse upon the Issuer entering into a definitive agreement or instrument pursuant to which, among other things, the Issuer would, directly or indirectly, merge into another person or entity or sell all or substantially all of its assets.
Item 5.     Interest in Securities of the Issuer.
Paragraphs (a), (b) and (e) of Item 5 are amended and restated in their entirety as follows:
(a) and (b)    The responses of the Reporting Person to rows 7, 8, 9, 10, 11 and 13 on the cover page of this Statement are incorporated herein by reference. As of the close of business on October 4, 2018, the Reporting Person beneficially owned 148,834 shares of Common Stock, representing approximately 4.99% of the outstanding shares of Common Stock. The percentage in this paragraph relating to beneficial ownership is based on 2,982,665 shares of Common Stock, which is the total number of shares of Common Stock of the Issuer estimated to be outstanding as of September 11, 2018, as reported in the Issuer’s Prospectus Supplement filed with the Securities and Exchange Commission on September 26, 2018.
(e)    Effective October 4, 2018, as a result of the letter agreement disclosed in Item 4 above, the Reporting Person ceased to be the beneficial owner of more than five percent of the Issuer’s Common Stock, par value $.001 per share.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities.

Item 6 is amended and restated in its entirety as follows:

Other than as described in this Statement, to the knowledge of the Reporting Person, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person or between the Reporting Person and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.


3

Item 7.     Material to be Filed as Exhibits.
Item 7 is amended to add the following:
 
 
Exhibit Number
Description
1
Letter agreement, dated as of October 4, 2018, between Kevin Pollack and Opiant Pharmaceuticals, Inc.


EXHIBIT INDEX









































4




SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

October 9, 2018         
Date
/s/ Kevin Pollack    
Signature
Kevin Pollack         
Name/Title




5
 EX-1 2 kevinpollack-letteragreeme.htm EXHIBIT 1 Exhibit
Exhibit 1

October 4, 2018

Opiant Pharmaceuticals, Inc.
Attn: Dr. Roger Crystal, Chief Executive Officer
201 Santa Monica Boulevard, Suite 500
Santa Monica, CA 90401

Re:    Beneficial Ownership Limitation

Dear Dr. Crystal:

Reference is made to the Separation Agreement and General Release (the “Agreement”), dated as of September 5, 2017, between Opiant Pharmaceuticals, Inc. (the “Company”) and myself. Capitalized terms not defined in this letter shall have the meanings ascribed to them in the Agreement.

The Company and I hereby agree as follows:

The Company shall not effect any exercise of the Retained Options, and I shall not have the right to exercise any portion of the Retained Options, to the extent that, after giving effect to such exercise, I (together with my Affiliates, and any persons acting as a group together with me or any of my Affiliates (such persons, “Attribution Parties”)) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of common stock of the Company (“Common Stock”) beneficially owned by me and my Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of the Retained Options with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon the exercise of the remaining, unexercised Retained Options beneficially owned by me or any of my Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To ensure compliance with this restriction, I will be deemed to represent to the Company each time that I (or a broker acting on my behalf) deliver a notice of exercise that such exercise will not violate the restrictions set forth in this paragraph, and the Company shall have no obligation to verify or confirm the accuracy of such representation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this paragraph, in determining the number of outstanding shares of Common Stock, I may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Company or (iii) a more recent written notice (which may be via email) by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding. Upon my written or oral request (which may be via email) from time to time, the Company shall within two (2) trading days of the date of such request confirm orally or via email to me the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the exercise or conversion of securities of the Company, including the Retained Options, by me or my Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of Retained Options. “Affiliate” means any person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person, as such terms are used in and construed under Rule 405 of the Securities Act of 1933, as amended (the “Securities Act”). I, upon not less than sixty-one

1
Exhibit 1

(61) days’ prior notice to the Company, may increase (but not above 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of Retained Options) or decrease the Beneficial Ownership Limitation provisions of this paragraph applicable to the Retained Options. Any such increase or decrease in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this paragraph to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of the Retained Options.

Notwithstanding the foregoing, the Beneficial Ownership Limitation shall automatically lapse and be of no further force and effect in the event that the Company enters into a definitive agreement or instrument pursuant to which: (i) the Company, directly or indirectly, in one or more related transactions would effect any merger or consolidation of the Company with or into another person(s) and/or entity(ies); (ii) the Company, directly or indirectly, would effect any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions; (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person(s) and/or entity(ies)) would be effectuated pursuant to which holders of Common Stock would be permitted to sell, tender or exchange their shares for other securities, cash or property; (iv) the Company, directly or indirectly, in one or more related transactions would effect any reclassification, reorganization and/or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock would effectively be converted into and/or exchanged for other securities, cash or property, and/or (v) the Company, directly or indirectly, in one or more related transactions would consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another person(s) and/or entity(ies) whereby such other person(s) and/or entity(ies) would acquire more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other person(s) and/or entity(ies) or other person(s) and/or entity(ies) making or party to, or associated or affiliated with the other person(s) and/or entity(ies) making or party to, such stock or share purchase agreement or other business combination).

For so long as the Beneficial Ownership Limitation is in effect, upon my written or oral request (which may be via email) from time to time, the Company shall within two (2) trading days confirm orally and via email to me (and/or to the Company’s transfer agent, any broker acting on my behalf and/or any other person(s) and/or entity(ies) requested by me) that neither I, nor any of my Affiliates nor any Attribution Party, is an “affiliate” under Rule 144 promulgated under the Securities Act.

Except as expressly provided above, the Company acknowledges and agrees that nothing contained in this letter agreement will amend or modify my rights, or the Company’s obligations, under the Agreement. This letter agreement may be executed in one or more original, facsimile or PDF counterparts, each of which shall be deemed to be an original and all of which together shall be considered one and the same instrument. Any notice provided by me under this letter agreement may be provided by email.








2
Exhibit 1


Sincerely,


/s/ Kevin Pollack
Kevin Pollack


ACKNOWLEDGED AND AGREED:

OPIANT PHARMACEUTICALS, INC.


By:     /s/ David O'Toole            
Name:         David O'Toole            
Title:         Chief Financial Officer    

3